WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Tyler D. Baguley
Patent Counselor
Patents and Innovations
San Diego
tbaguley@wsgr.com

D858-350-2278

Download vCard
Open PDF

Dr. Tyler Baguley is a patent counselor in the San Diego office of Wilson Sonsini Goodrich & Rosati. He assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology.

Prior to joining the firm, Tyler was a postdoctoral fellow on the medicinal chemistry team at the California Institute for Biomedical Research in La Jolla. In this role, he focused on the design and synthesis of organic small molecules to treat a variety of disease indications such as diabetes, fibrosis, and infectious disease. During his doctoral studies at the University of California, Berkeley, he developed inhibitors of protein tyrosine phosphatases, as well as new synthetic methodologies. He has co-authored several scientific publications and is a co-inventor on three U.S. patent applications.

Experience

Dr. Tyler Baguley is a patent counselor in the San Diego office of Wilson Sonsini Goodrich & Rosati. He assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology.

Prior to joining the firm, Tyler was a postdoctoral fellow on the medicinal chemistry team at the California Institute for Biomedical Research in La Jolla. In this role, he focused on the design and synthesis of organic small molecules to treat a variety of disease indications such as diabetes, fibrosis, and infectious disease. During his doctoral studies at the University of California, Berkeley, he developed inhibitors of protein tyrosine phosphatases, as well as new synthetic methodologies. He has co-authored several scientific publications and is a co-inventor on three U.S. patent applications.

Education
  • Ph.D., Chemistry, University of California, Berkeley, 2014
  • B.S., Biochemistry, University of Oregon, 2008Summa Cum Laude; Departmental Honors; Recipient, 2008 Organic Chemistry Achievement Award; Minor in Mathematics
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Chemistry, University of California, Berkeley, 2014
  • B.S., Biochemistry, University of Oregon, 2008Summa Cum Laude; Departmental Honors; Recipient, 2008 Organic Chemistry Achievement Award; Minor in Mathematics
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author with H.-C. Xu, M. Chatterjee, A.C. Nairn, P.J. Lombroso, and J.A. Ellman, "Substrate-Based Fragment Identification for the Development of Selective, Nonpeptidic Inhibitors of Striatal-Enriched Protein Tyrosine Phosphatase," 56(19) Journal of Medicinal Chemistry 7636-50, 2013
  • Co-author with J. Xu, M. Chatterjee, J. Brouillette, P. Kurup, J. Kanyo, Y. Zhang, K. Seyb, C. Ononenyi, G.M. Anderson, J. Gresack, G.D. Cuny, M.A. Glicksman, P. Greengard, T.T. Lam, A.C. Nairn, L. Tautz, J.A. Ellman, and P.J. Lombroso, "Inhibitors of the tyrosine phosphatase STEP Reverse Cognitive Deficits in a Mouse Model of Alzheimer's Disease," 12(8) PLoS Biology, 2014
  • Co-author with A.C. Nairn, P.J. Lombroso, and J.A. Ellman, "Synthesis of 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) analogs and evaluation as inhibitors of STEP," 25(5) Bioorganic & Medicinal Chemistry Letters 1050-52, 2015
  • Co-author with A.W. Buesking and J.A. Ellman, "Asymmetric Synthesis of Amines by the Knochel-Type MgCl2-Enhanced Addition of Benzyl Zinc Reagents to N-tert-Butanesulfinyl Aldimines," 13(5) Organic Letters 964-7, 2011
Insights

Select Publications

  • Co-author with H.-C. Xu, M. Chatterjee, A.C. Nairn, P.J. Lombroso, and J.A. Ellman, "Substrate-Based Fragment Identification for the Development of Selective, Nonpeptidic Inhibitors of Striatal-Enriched Protein Tyrosine Phosphatase," 56(19) Journal of Medicinal Chemistry 7636-50, 2013
  • Co-author with J. Xu, M. Chatterjee, J. Brouillette, P. Kurup, J. Kanyo, Y. Zhang, K. Seyb, C. Ononenyi, G.M. Anderson, J. Gresack, G.D. Cuny, M.A. Glicksman, P. Greengard, T.T. Lam, A.C. Nairn, L. Tautz, J.A. Ellman, and P.J. Lombroso, "Inhibitors of the tyrosine phosphatase STEP Reverse Cognitive Deficits in a Mouse Model of Alzheimer's Disease," 12(8) PLoS Biology, 2014
  • Co-author with A.C. Nairn, P.J. Lombroso, and J.A. Ellman, "Synthesis of 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) analogs and evaluation as inhibitors of STEP," 25(5) Bioorganic & Medicinal Chemistry Letters 1050-52, 2015
  • Co-author with A.W. Buesking and J.A. Ellman, "Asymmetric Synthesis of Amines by the Knochel-Type MgCl2-Enhanced Addition of Benzyl Zinc Reagents to N-tert-Butanesulfinyl Aldimines," 13(5) Organic Letters 964-7, 2011

Therapeutics and Drug Discovery

  • Small molecule synthesis
  • Small molecules

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Organic chemistry
Technical Fluency

Therapeutics and Drug Discovery

  • Small molecule synthesis
  • Small molecules

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Organic chemistry
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Crinetics on Patent Matters Related to Public Offering
On January 6, 2026, Crinetics Pharmaceuticals, a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics, and the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350 million. Wilson Sonsini Goodrich & Rosati advised Crinetics on patent matters related to the public offering.
Learn More
Client Highlights
Wilson Sonsini Advises Crinetics Pharmaceuticals on Patent Matters Related to Upsized $500 Million Common Stock Offering
On October 8, 2024, Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the pricing of an upsized underwritten public offering of 10 million shares of its common stock at a price to the public of $50.00 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock. Wilson Sonsini Goodrich & Rosati is advising Crinetics on patent matters related to the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.